Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes
- Authors: Fazylov V.C.1, Tkacheva S.V.1, Manapova E.R.1, Jakupova F.M.1
-
Affiliations:
- Kazan State Medical University, Ministry of Health of the Russian Federation
- Issue: Vol 60, No 1 (2015)
- Pages: 28-31
- Section: ORIGINAL RESEARCH
- URL: https://ogarev-online.ru/0507-4088/article/view/118053
- ID: 118053
Cite item
Full Text
Abstract
The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-a, interleukin-1β (IL-1β) and interferon-gamma (IFN-y) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-a and ribavirin in patients with recurrent HCV-infection.
About the authors
V. Ch. Fazylov
Kazan State Medical University, Ministry of Health of the Russian Federation
Author for correspondence.
Email: vildan47@rambler.ru
Vil’dan Fazylov, MD, PhD, DSc
420012, Kazan
Russian FederationS. V. Tkacheva
Kazan State Medical University, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
420012, Kazan Russian Federation
E. R. Manapova
Kazan State Medical University, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
420012, Kazan Russian Federation
F. M. Jakupova
Kazan State Medical University, Ministry of Health of the Russian Federation
Email: fake@neicon.ru
420012, Kazan Russian Federation
References
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J. Hepatol. 2011; 55: 245–64.
- Hadziyannis S.J., Sette H.Jr., Morgan T.R., Balan V., Diago M., Marcellin P. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004; 140 (5): 346–55.
- Bruno R., Brunetti E., Maffezzini E. et al. Daily dose interferon for chronic hepatitis C: a prospective randomized study. Hepatology. 1998; 28: (4), pt. 2: 572A, abstr. 1637.
- Еналеева Д.Ш., Фазылов В.Х., Созинов А.С. Хронические вирусные гепатиты В, С и D. М.: «Медпресс-информ»; 2011: 257–9.
- Никитин И.Г., Гогова Л.М., Байкова И.Е. и др. Человеческий лейкоцитарный альфа-интерферон в комбинированной терапии больных хроническим гепатитом С, инфицированных не 1-м генотипом вируса. Клинические перспективы гастроэнтерологии, гепатологии. 2009; 1: 33–7.
- Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology. 2010; 138: 1338–45.
- Козина А.Н. Возможности персонифицированного подхода к лечению гепатита С на основании разработанных генетических тестов определения варианта полиморфизма гена ИЛ-28B / А.Н. Козина, Д.Д. Абрамов, Е.А. Климова и др. Лечащий врач. 2011; 10: 39–43.
- McCarthy J., Li J., Thompson A. et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138: 2307–14.
- Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology. 2010; 138: 1338–45.
Supplementary files
